Consensus Statement
|
Open Access
Featured
-
-
Comment |
Adverse effects of SGLT2 inhibitors on bone health
Sodium–glucose cotransporter 2 (SGLT2) inhibitors provide metabolic and cardiorenal benefits for patients with type 2 diabetes but are associated with a number of safety issues. Here, we discuss evidence suggesting that indirect activation of the FGF23–1,25-dihydroxyvitamin D–parathyroid hormone axis by SGLT2 inhibition might contribute to adverse effects on bone health.
- Jenny E. Blau
- & Simeon I. Taylor
-
-